Allogene Therapeutics (ALLO) Intangibles (2018 - 2019)
Allogene Therapeutics (ALLO) posted Intangibles of $151000.0 for Q4 2019, down 49.83% sequentially from $301000.0 in Q3 2019, and down 79.97% YoY from $754000.0 in Q4 2018.
Powered by 
Analysis
Allogene Therapeutics (ALLO) Intangibles (2018 - 2019) Analysis & Trends
Allogene Therapeutics has reported Intangibles for 2 years, with the latest figure at $151000.0 in Q4 2019.
- Quarterly Intangibles fell 79.97% year-over-year to $151000.0 in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $151000.0 (down 79.97% YoY) and the FY2019 annual result came in at $151000.0, down 79.97% from the prior year.
- Intangibles slipped to $151000.0 in Q4 2019 per ALLO's latest filing, from $301000.0 in the prior quarter.
- Over five years, Intangibles peaked at $904000.0 in Q3 2018 and troughed at $151000.0 in Q4 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 266.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 63.28 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 60.96 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Allogene Therapeutics | 647.99 Mn | 647.99 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2019 | 151,000.00 |
| Sep 30, 2019 | 301,000.00 |
| Jun 30, 2019 | 452,000.00 |
| Mar 31, 2019 | 603,000.00 |
| Dec 31, 2018 | 754,000.00 |
| Sep 30, 2018 | 904,000.00 |